Ignacio Muñoz-Sanjuán, Cajal Neuroscience CEO

Ca­jal Neu­ro­science launch­es with $96M Se­ries A, tack­ling Alzheimer's and Parkin­son's

Ca­jal Neu­ro­science has emerged with a $96 mil­lion Se­ries A and plans to dis­cov­er drug can­di­dates in Alzheimer’s and Parkin­son’s with a wealth of gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.